These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22094968)

  • 21. Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis?
    Qayyum F; Holbrook A; Lam J; Kovacs MJ; Schulman S
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):705-13. PubMed ID: 23080362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes.
    Vardi M; Laor A; Bitterman H
    Thromb Haemost; 2009 Nov; 102(5):879-86. PubMed ID: 19888523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antithrombotic therapy and survival in cancer patients.
    Kakkar AK
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):147-51. PubMed ID: 19285281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low molecular weight heparins in cancer. Management and prevention of venous thromboembolism in patients with malignancies.
    ten Cate-Hoek AJ; Prins MH
    Thromb Res; 2008; 122(5):584-98. PubMed ID: 17996281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients.
    Levine M
    Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():9-11. PubMed ID: 14730472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
    Arch Intern Med; 1997 Nov; 157(20):2317-21. PubMed ID: 9361572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development in anticoagulant therapy.
    van Doormaal FF; Büller HR; Middeldorp S
    Crit Rev Oncol Hematol; 2008 May; 66(2):145-54. PubMed ID: 18032061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of deep vein thrombosis in cancer patients.
    Lee AY
    Semin Thromb Hemost; 2007 Oct; 33(7):699-706. PubMed ID: 18000798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism.
    Rhodes S; Bond S
    Eur J Oncol Nurs; 2008 Dec; 12(5):425-9. PubMed ID: 18842458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombocytopenia and other hot topics.
    DeLoughery TG
    Am J Clin Oncol; 2009 Aug; 32(4 Suppl):S13-7. PubMed ID: 19654480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of venous thromboembolism in cancer patients.
    Lee AY
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):93-101. PubMed ID: 19285276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The treatment of deep venous thrombosis with low-molecular-weight heparin].
    Samama MM; Achkar A; Horellou MH
    Rev Med Brux; 1995; 16(4):304-9. PubMed ID: 7481248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients?
    Caine GJ; Lip GY
    Arch Intern Med; 2003 May; 163(10):1243-4; author reply 1244. PubMed ID: 12767973
    [No Abstract]   [Full Text] [Related]  

  • 36. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism.
    Hirsh J; Siragusa S; Cosmi B; Ginsberg JS
    Thromb Haemost; 1995 Jul; 74(1):360-3. PubMed ID: 8578485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory monitoring of anticoagulation: where do we stand?
    Tripodi A; van den Besselaar A
    Semin Thromb Hemost; 2009 Feb; 35(1):34-41. PubMed ID: 19308891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is unfractionated heparin equivalent to low-molecular-weight heparin for venous thromboembolism?
    Graber MA; Dachs R; Darby-Stewart A
    Am Fam Physician; 2008 Jun; 77(11):1492-3. PubMed ID: 18581828
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of venous thrombosis in cancer patients: practical aspects].
    Laza-Achille M; Desruennes E; Di Palma M
    Bull Cancer; 2006 Mar; 93(3):271-81. PubMed ID: 16567314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Conventional or low molecular weight heparin in the treatment of venous thromboembolic disease?].
    Ruiz Manzano J; Monreal M
    Med Clin (Barc); 1998 Nov; 111(18):697-9. PubMed ID: 9887434
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.